ATE319683T1 - Selektive 5-ht 6-rezeptor-liganden - Google Patents

Selektive 5-ht 6-rezeptor-liganden

Info

Publication number
ATE319683T1
ATE319683T1 AT99967248T AT99967248T ATE319683T1 AT E319683 T1 ATE319683 T1 AT E319683T1 AT 99967248 T AT99967248 T AT 99967248T AT 99967248 T AT99967248 T AT 99967248T AT E319683 T1 ATE319683 T1 AT E319683T1
Authority
AT
Austria
Prior art keywords
selective
receptor ligands
receptors
compounds
treatment
Prior art date
Application number
AT99967248T
Other languages
English (en)
Inventor
Richard A Glennon
Bryan L Roth
Original Assignee
Univ Virginia Commonwealth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia Commonwealth filed Critical Univ Virginia Commonwealth
Application granted granted Critical
Publication of ATE319683T1 publication Critical patent/ATE319683T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Escalators And Moving Walkways (AREA)
  • Electric Double-Layer Capacitors Or The Like (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Control Of High-Frequency Heating Circuits (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Conductive Materials (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT99967248T 1998-12-11 1999-12-10 Selektive 5-ht 6-rezeptor-liganden ATE319683T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11178798P 1998-12-11 1998-12-11

Publications (1)

Publication Number Publication Date
ATE319683T1 true ATE319683T1 (de) 2006-03-15

Family

ID=22340454

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99967248T ATE319683T1 (de) 1998-12-11 1999-12-10 Selektive 5-ht 6-rezeptor-liganden

Country Status (10)

Country Link
EP (1) EP1149078B1 (de)
AT (1) ATE319683T1 (de)
AU (1) AU767009B2 (de)
CA (1) CA2353962C (de)
DE (1) DE69930308T2 (de)
DK (1) DK1149078T3 (de)
ES (1) ES2260958T3 (de)
MX (1) MXPA01005905A (de)
PT (1) PT1149078E (de)
WO (1) WO2000034242A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100823908B1 (ko) 2000-10-20 2008-04-21 바이오비트럼 에이비(피유비엘) 2-, 3-, 4-, 또는 5-치환-ｎ1-(벤젠술포닐)인돌 및 이의치료 용도
SI1379239T1 (sl) * 2001-03-29 2008-02-29 Lilly Co Eli N-(2-ariletil)benzilamini, uporabljeni kot antagonisti receptorja 5-ht6
ES2566056T3 (es) * 2001-03-29 2016-04-08 Eli Lilly And Company N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
CN100457726C (zh) 2001-06-11 2009-02-04 比奥维特罗姆股份公开公司 取代的磺酰胺化合物、其制备方法及其作为治疗cns疾病、肥胖和ⅱ型糖尿病的药物的应用
ITRM20010356A1 (it) * 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
EP1897881A3 (de) 2002-06-20 2009-03-18 Biovitrum AB (publ) Zur Behandlung von Obesitas, Typ II-Diabetes und ZNS-Erkrankungen geeignete Verbindungen
ES2297216T3 (es) 2002-06-21 2008-05-01 Suven Life Sciences Limited Indoles tetraciclicos arilsulfonil que tienen afinidad con el receptor de la serotonina.
JP4571507B2 (ja) * 2002-12-18 2010-10-27 スベン ライフ サイエンシズ リミティド セロトニン受容体親和性を有する四環系３−置換インドール
US7465815B2 (en) 2003-06-26 2008-12-16 Takeda Pharmaceutical Company Limited Cannabinoid receptor modulator
WO2005012311A1 (en) * 2003-07-31 2005-02-10 Wyeth N-sulfonylheterocyclopyrrolylalkylamine compounds as 5-hydroxytryptamine-6 ligands
SE0303480D0 (sv) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
BRPI0517955A (pt) 2004-11-01 2008-10-21 Wyeth Corp indolizinas substituìdas e derivados como agentes de snc
US7582767B2 (en) 2005-06-17 2009-09-01 Biovitrum Ab (Publ.) Substituted sulphonamide compound and uses thereof
JP2009512681A (ja) * 2005-10-19 2009-03-26 スヴェン・ライフ・サイエンシズ・リミテッド 機能性５−ｈｔ６リガンドとしてのカルバゾール誘導体
US8138333B2 (en) 2007-03-13 2012-03-20 Proximagen Limited Sulfonyl-indole derivatives
JP2011505418A (ja) 2007-12-04 2011-02-24 メルク・シャープ・エンド・ドーム・コーポレイション ５−ｈｔ６アンタゴニストとしてのトリプタミンスルホンアミド
EP2103596A1 (de) 2008-03-18 2009-09-23 Laboratorios Del. Dr. Esteve, S.A. Verfahren zur Herstellung von N-(Phenylethyl)-Anilinsalzen und deren Solvate zur nützlichen Verwendung als Serotonin-5-HT6-Antagonisten
GB0905328D0 (en) * 2009-03-27 2009-05-13 Ge Healthcare Ltd Indole derivatives
FR2961095B1 (fr) * 2010-06-09 2012-06-15 Oreal Composition cosmetique et/ou dermatologique comprenant au moins un compose 6-alcoxy tryptamine
FR2961097B1 (fr) * 2010-06-09 2012-07-13 Oreal Procede cosmetique de traitement des odeurs corporelles humaines utilisant un compose 6-alkoxy tryptamine
US9073851B2 (en) 2011-10-28 2015-07-07 Board Of Regents, The University Of Texas System Compositions and methods for treating cancer
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
CA3201913A1 (en) 2020-12-09 2022-06-16 Andrew R. Chadeayne Dialkyl trytamines and their therapeutic uses
CA3244229A1 (en) * 2021-12-24 2023-06-29 Psylo Pty Ltd COMPOUNDS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
GB8416724D0 (en) * 1984-06-30 1984-08-01 Sorbio Sa Lab Active compounds

Also Published As

Publication number Publication date
CA2353962C (en) 2009-09-29
AU767009B2 (en) 2003-10-30
EP1149078A4 (de) 2003-01-29
EP1149078B1 (de) 2006-03-08
DK1149078T3 (da) 2006-07-10
AU2356200A (en) 2000-06-26
DE69930308T2 (de) 2006-11-30
WO2000034242A1 (en) 2000-06-15
EP1149078A1 (de) 2001-10-31
DE69930308D1 (de) 2006-05-04
MXPA01005905A (es) 2002-09-18
ES2260958T3 (es) 2006-11-01
CA2353962A1 (en) 2000-06-15
PT1149078E (pt) 2006-07-31

Similar Documents

Publication Publication Date Title
DE69930308D1 (de) Selektive 5-ht 6-rezeptor-liganden
DK1588706T3 (da) Valsartantablet
DK1196397T3 (da) Metabotrope glutamatreceptorantagonister og anvendelse deraf til behandling af sygdomme i centralnervesystemet
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
EA200200560A1 (ru) Полициклоалкилпурины в качестве антагонистов аденозиновых рецепторов
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
NO20015413D0 (no) Anvendelse av dopamin-D3-reseptor-ligander for fremstilling av medikamenter for behandling av nyrefunksjonsforstyrrelser
FR2799124B1 (fr) Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
DE60203797D1 (de) Benzo[d]azepin-derivative als 5-ht6-rezeptor-antagonisten
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
EA199900912A1 (ru) Фармацевтические средства
MXPA04006555A (es) Piridazinodionas-3,4-disustituidas como antagonistas de receptor de quimiocina cxc.
EE9900595A (et) Spetsiifilise 5-HT 2A-retseptori antagonisti kasutamine une hingamishäirete raviks kasulike ravimite valmistamiseks
AP2002002420A0 (en) Fused pyrrolecarboxamides: gaba brain receptor ligands.
HUP0203338A2 (hu) Integrin receptor ligandumok
TR200100240T2 (tr) Anksiyete bozukluklarının tedavisi
PT883401E (pt) Antagonista do receptor at1 para estimulacao da apoptose
WO2002017922A8 (en) Bridged nicotine compounds for use in the treatment of cns pathologies
NO981188D0 (no) 5-HT3-reseptorantagonister for dyskinesi
TNSN00178A1 (en) Fused pyrrolecaboxamides; a new class of gaba brain receptor ligands
DE69901716D1 (de) Pharmazeutische zusammensetzung enthaltend factor xiiia für nervenheilung
ITMI940223A0 (it) N-acetiltriptamine-2-sostituite, antagoniste ad elevata affinita' del recettore della melatonina

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1149078

Country of ref document: EP

REN Ceased due to non-payment of the annual fee